ID

23430

Description

Effect of Nuts vs. a Wheat Bran Muffin in Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00410722

Lien

https://clinicaltrials.gov/show/NCT00410722

Mots-clés

Versions (1)
  1. 04/07/2017 04/07/2017 -
Téléchargé le

4 juillet 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes NCT00410722

Anglais

Eligibility Type 2 Diabetes NCT00410722

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
men and post menopausal women with type 2 diabetes treated with diet plus oral hypoglycemic agents (sulfonylureas (glyburide), biguanides (metformin), thiazolidinediones (tzds) and new secretagogues (repaglinide)) at a stable dose for at least 3 months prior to starting the study;
Description

Gender | Postmenopausal state | Diabetes Mellitus, Non-Insulin-Dependent | Diet therapy | Oral hypoglycemic Dose Stable | Sulfonylurea | Glyburide | Biguanides | Metformin | Thiazolidinediones | repaglinide

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0232970
UMLS CUI [3]
C0011860
UMLS CUI [4]
C0012159
UMLS CUI [5,1]
C0359086
UMLS CUI [5,2]
C0178602
UMLS CUI [5,3]
C0205360
UMLS CUI [6]
C0038766
UMLS CUI [7]
C0017628
UMLS CUI [8]
C0005382
UMLS CUI [9]
C0025598
UMLS CUI [10]
C1257987
UMLS CUI [11]
C0246689
hba1c of 6.5 to 8.0% as a compromise between those whose levels are acceptable and the level which is currently considered unacceptable.
Description

Glycosylated hemoglobin A

Type de données

boolean

Alias
UMLS CUI [1]
C0019018
diabetes diagnosed >6 months prior to randomization
Description

Diabetes Mellitus disease length

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011849
UMLS CUI [1,2]
C0872146
weight stable within 3% body weight >2 months.
Description

Stable body weight

Type de données

boolean

Alias
UMLS CUI [1]
C0517386
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of acarbose
Description

Acarbose

Type de données

boolean

Alias
UMLS CUI [1]
C0050393
use of insulin
Description

Insulin

Type de données

boolean

Alias
UMLS CUI [1]
C0021641
known nut allergies
Description

Nut Hypersensitivity

Type de données

boolean

Alias
UMLS CUI [1]
C0577620
clinically significant gastroparesis
Description

Gastroparesis

Type de données

boolean

Alias
UMLS CUI [1]
C0152020
use of steroids
Description

Steroids

Type de données

boolean

Alias
UMLS CUI [1]
C0038317
presence of gi disease (celiac disease, ulcerative colitis, and crohns)
Description

Gastrointestinal Diseases | Celiac Disease | Ulcerative Colitis | Crohn Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0017178
UMLS CUI [2]
C0007570
UMLS CUI [3]
C0009324
UMLS CUI [4]
C0010346
major cardiovascular event (stroke or myocardial infarction)
Description

Cardiovascular event Major | Cerebrovascular accident | Myocardial Infarction

Type de données

boolean

Alias
UMLS CUI [1,1]
C1320716
UMLS CUI [1,2]
C0205164
UMLS CUI [2]
C0038454
UMLS CUI [3]
C0027051
major surgery < 6 months prior to randomization
Description

major surgery

Type de données

boolean

Alias
UMLS CUI [1]
C0679637
presence of major debilitating disorder such as clinically significant liver disease (not including non-alcoholic fatty liver (nafl) or non-alcoholic steatohepatitis (nash) but including cirrhosis, infectious hepatitis (b and c), aspartate transaminase (ast) or alanine transaminase (alt) > 130 iu/l)
Description

Debilitation Major | Liver diseases | Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Cirrhosis | HEPATITIS B INFECTIOUS | Hepatitis C | Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0742985
UMLS CUI [1,2]
C0205164
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0400966
UMLS CUI [4]
C3241937
UMLS CUI [5]
C0023890
UMLS CUI [6]
C0744836
UMLS CUI [7]
C0019196
UMLS CUI [8]
C0201899
UMLS CUI [9]
C0201836
renal failure (high creatinine > 150 mmol/l)
Description

Kidney Failure | Creatinine increased

Type de données

boolean

Alias
UMLS CUI [1]
C0035078
UMLS CUI [2]
C0151578
serum triglyceride > 6 mmol/l.
Description

Serum Triglyceride Measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0542495
patients currently undergoing treatment for cancer with the exception of non-melanoma skin cancer, but not high risk patients or those whose treatment has been successfully completed.
Description

Cancer treatment | Skin carcinoma | High risk Absent | Treatment completed Successful

Type de données

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0699893
UMLS CUI [3,1]
C0332167
UMLS CUI [3,2]
C0332197
UMLS CUI [4,1]
C0580352
UMLS CUI [4,2]
C1272703
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes NCT00410722

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Postmenopausal state | Diabetes Mellitus, Non-Insulin-Dependent | Diet therapy | Oral hypoglycemic Dose Stable | Sulfonylurea | Glyburide | Biguanides | Metformin | Thiazolidinediones | repaglinide
Item
men and post menopausal women with type 2 diabetes treated with diet plus oral hypoglycemic agents (sulfonylureas (glyburide), biguanides (metformin), thiazolidinediones (tzds) and new secretagogues (repaglinide)) at a stable dose for at least 3 months prior to starting the study;
boolean
C0079399 (UMLS CUI [1])
C0232970 (UMLS CUI [2])
C0011860 (UMLS CUI [3])
C0012159 (UMLS CUI [4])
C0359086 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0205360 (UMLS CUI [5,3])
C0038766 (UMLS CUI [6])
C0017628 (UMLS CUI [7])
C0005382 (UMLS CUI [8])
C0025598 (UMLS CUI [9])
C1257987 (UMLS CUI [10])
C0246689 (UMLS CUI [11])
Glycosylated hemoglobin A
Item
hba1c of 6.5 to 8.0% as a compromise between those whose levels are acceptable and the level which is currently considered unacceptable.
boolean
C0019018 (UMLS CUI [1])
Diabetes Mellitus disease length
Item
diabetes diagnosed >6 months prior to randomization
boolean
C0011849 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Stable body weight
Item
weight stable within 3% body weight >2 months.
boolean
C0517386 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Acarbose
Item
use of acarbose
boolean
C0050393 (UMLS CUI [1])
Insulin
Item
use of insulin
boolean
C0021641 (UMLS CUI [1])
Nut Hypersensitivity
Item
known nut allergies
boolean
C0577620 (UMLS CUI [1])
Gastroparesis
Item
clinically significant gastroparesis
boolean
C0152020 (UMLS CUI [1])
Steroids
Item
use of steroids
boolean
C0038317 (UMLS CUI [1])
Gastrointestinal Diseases | Celiac Disease | Ulcerative Colitis | Crohn Disease
Item
presence of gi disease (celiac disease, ulcerative colitis, and crohns)
boolean
C0017178 (UMLS CUI [1])
C0007570 (UMLS CUI [2])
C0009324 (UMLS CUI [3])
C0010346 (UMLS CUI [4])
Cardiovascular event Major | Cerebrovascular accident | Myocardial Infarction
Item
major cardiovascular event (stroke or myocardial infarction)
boolean
C1320716 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0038454 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
major surgery
Item
major surgery < 6 months prior to randomization
boolean
C0679637 (UMLS CUI [1])
Debilitation Major | Liver diseases | Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Cirrhosis | HEPATITIS B INFECTIOUS | Hepatitis C | Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
presence of major debilitating disorder such as clinically significant liver disease (not including non-alcoholic fatty liver (nafl) or non-alcoholic steatohepatitis (nash) but including cirrhosis, infectious hepatitis (b and c), aspartate transaminase (ast) or alanine transaminase (alt) > 130 iu/l)
boolean
C0742985 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2])
C0400966 (UMLS CUI [3])
C3241937 (UMLS CUI [4])
C0023890 (UMLS CUI [5])
C0744836 (UMLS CUI [6])
C0019196 (UMLS CUI [7])
C0201899 (UMLS CUI [8])
C0201836 (UMLS CUI [9])
Kidney Failure | Creatinine increased
Item
renal failure (high creatinine > 150 mmol/l)
boolean
C0035078 (UMLS CUI [1])
C0151578 (UMLS CUI [2])
Serum Triglyceride Measurement
Item
serum triglyceride > 6 mmol/l.
boolean
C0542495 (UMLS CUI [1])
Cancer treatment | Skin carcinoma | High risk Absent | Treatment completed Successful
Item
patients currently undergoing treatment for cancer with the exception of non-melanoma skin cancer, but not high risk patients or those whose treatment has been successfully completed.
boolean
C0920425 (UMLS CUI [1])
C0699893 (UMLS CUI [2])
C0332167 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0580352 (UMLS CUI [4,1])
C1272703 (UMLS CUI [4,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial